Cocrystal Pharma, Inc.
COCP
$1.31
$0.010.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -59.68% | -62.94% | -50.63% | -22.97% | -17.35% |
| Gross Profit | 59.68% | 62.94% | 50.63% | 22.97% | 17.35% |
| SG&A Expenses | -25.78% | -22.57% | -11.37% | -14.68% | -10.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.55% | -51.91% | -40.32% | -20.51% | -15.51% |
| Operating Income | 49.55% | 51.91% | 40.32% | 20.51% | 15.51% |
| Income Before Tax | 49.55% | 48.29% | 29.94% | 5.38% | 2.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.55% | 48.29% | 29.94% | 5.38% | 2.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.55% | 48.29% | 29.94% | 5.38% | 2.67% |
| EBIT | 49.55% | 51.91% | 40.32% | 20.51% | 15.51% |
| EBITDA | 49.60% | 52.02% | 40.36% | 20.40% | 15.35% |
| EPS Basic | 54.07% | 49.05% | 29.88% | 5.56% | 9.35% |
| Normalized Basic EPS | 54.06% | 51.63% | 38.77% | 18.23% | 20.12% |
| EPS Diluted | 54.07% | 49.05% | 29.88% | 5.56% | 9.49% |
| Normalized Diluted EPS | 54.06% | 51.63% | 38.77% | 18.23% | 20.12% |
| Average Basic Shares Outstanding | 10.95% | 1.89% | -0.06% | 0.20% | 5.48% |
| Average Diluted Shares Outstanding | 10.95% | 1.89% | -0.06% | 0.20% | 5.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |